Introduction {#sec0005}
============

*Rhodococcus* is a Gram-positive coccobacillus that belongs to the *Actinomicetae* order \[[@bib0005]\] This microorganism has been described as cause of infection in immunocompromised host such as Human Immunodeficiency Virus (HIV) and solid organ transplantation patients \[[@bib0005],[@bib0010]\]. Moreover, few cases have been reported in hematopoietic stem cell transplantation (HSCT) patients, mostly in allogeneic (allo) patients with graft versus host diseases (GVHD) \[[@bib0015]\].

Case report {#sec0010}
===========

We present the case of a 37-year-old woman with acute myeloid leukemia (AML), colonized by vancomycin-resistant *Enterococcus* (VRE) who received an allo-HSCT from HLA compatible donor 5 months prior to admission. Bulsuphan, Fludarabine and Alemtuzumab were used as conditioning agents. The patient developed cutaneous and gastrointestinal tract GVHD, respectively on day 29 and 69. On day 69, she presented reactivation of cytomegalovirus (CMV) (RT-PCR CMV 6027 UI/mL, negativation within 3 weeks).

On day 119, she was admitted to the hospital with dyspnea and cough, the baseline liver enzymes were normal (ALT 10 U/L and AST 15 U/L) and blood count (Hb = 7,0 gm/dL; Ht = 20,9%; leukocytes 940 cells/m3; neutrophils 790 cells/m3 and platelets 159,000). The chest computer tomography (CT) revealed opacities in the upper lobe of right lung and absence of halo sign, both galactomannan on bronchoalveolar lavage fluid and serum were positives (0.5 ODI and 0.73 ODI respectively) ([Fig. 1](#fig0005){ref-type="fig"}). Thus, she started voriconazole (200 mg IV q 12 h), that was replaced later on by liposomal Amphotericin B (LAmB) 300 mg/d because of increased rates of liver enzymes (ALT 166 U/L and AST 85 U/L). Voriconazole was reintroduced (200 mg IV q12 h) when the liver enzymes were normal. There was improvement of pulmonary symptoms and radiological images with non-invasive ventilation after 23 days of antifungal drugs and GVHD treatment (metilprednisolone 90 mg/d) ([Fig. 1](#fig0005){ref-type="fig"}). The patient was discharged from the hospital on day 142.Fig. 1Pulmonary CT before HSCT.Pulmonary CT day 119 HSCT.Fig. 1

On day 145, three days after she was discharged, the patient was hospitalized with dyspnea, acute kidney injury and CMV reactivation (RT-PCR CMV 401UI/mL) that was treated with ganciclovir (2,5 mg/kg/d IV q 12 h) adjusted for kidney function (KDIGO II). Blood cultures were collected, voriconazole was replaced by LAmB (3 mg/kg/d) and piperacilin-tazobactam (4,0 mg IV q6h) was introduced. On day 157 she evolved to acute severe respiratory failure and renal replacement therapy. She was transfer to the intensive care unit and mechanic ventilation was started. In this context, cultures were collected and trimethoprim/sulfamethoxazole (trimethoprim 15 mg/kg/d IV q6h), meropenem (1g IV q12h), colistin 2,5 mg/kg/d IV qDay), amikacin (15 mg/kg/d q24h) and linezolid (600 mg q12h) were given. Bronchoalveolar lavage was performed and Ziehl-Nielsen staining, bacteria and fungi cultures, Multiplex PCR for virus and galactomannan were negatives. Pulmonary CT before HSCT showed sparse and bilateral micronodules, measuring up to 0.3 cm and stable calcifications. Pulmonary CT on day 119 HSCT showed sparse nodules and micronodules, pneumonic foci in organization and opacity in frosted glass ([Fig. 1](#fig0005){ref-type="fig"}).

After five days, blood cultures were positive for *Achromobacter* sp. and *Rhodococcus* sp. using VITEK® Biomerieux-France and matrix-assisted laser desorption ionization with time of flight (MALDI-TOF-Biomerieux-France). We performed the sequencing of 16S ribosomal RNA gene (16S rRNA gene) of *Rhodococcus* sp to confirmed the identification that revealed 100 % of identity with *Rhodococcus hoagii* according to the National Center for Biotechnology Information (NCBI) database. Genebank access number SUB4217796 Seq1 MH539885.

The central venous catheter was removed, moreover, despite the treatment with active antibiotics against *R. hoagie* as linezolid, amikacin and meropenem for 14 days, the patient evolved with multi organ dysfunction syndrome and death on day 172 ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2Timeline showing main events that occurred during patient treatment.Fig. 2

Discussion {#sec0015}
==========

We present here a case report of a bloodstream infection (BSI) caused by *R. hoagii* in an allo-HSCT patient who evolved to death. This bacterium has been associated with severe infections such as BSI and pneumonia with high mortality in this population of patient; mainly allo-HSCT patients ([Table 1](#tbl0005){ref-type="table"}).Table 1Cases of *Rhodococcus* in allo-HSCT patients described in the literature.Table 1Year (Reference)Age yearsGenderRhodococcus speciesComorbiditiesClinical diagnosisTreatmentOutcome1995 (10)29Male*R. equi*LymphomaPneumniaNot reportedDeath2008 (4)61Male*R. equi*LymphomaPneumniaVancomycin (treatment failure); ertapenem and rifampicinCure2012 (11)60Male*R. equi*T-cell prolymphocytic LeukemiaLung nass, pleual malakoplakiaRight upperlobe lobectomyCure2012 (5)64Male*R. corynebacteoides*Myelodysplastic syndromeBacteremiacefepime and cefozopranDeath2012 (8)68Male*R. equi*Not InformedMediastinitisVancomycin and ciprofloxacinNot repoted2013 (7)61Male*R. globerulus*Acute Myelomonocytic LeukemiaBacteremiaVancomycin and ciprofloxacinCure2017 (present case)37Female*R. equi*Acute Myeloid LeukemiaPneumoniaMeropenem, amicakin and linezolidDeath

*Rhodococcus* has been associated to exposure to rural areas. It transmission usually occurs by inhalation of contaminated soils; as the soils of horses 's farmers contains highly concentration of this bacteria \[[@bib0005],[@bib0020],[@bib0025]\]. Recently its taxonomy changed based on sequencing methods, thus, *Rhodococcus equi* was named as *R. hoagii* according to the rules of the Bacteriological Code \[[@bib0070]\]. Although the 16S rRNA gene sequencing analysis is an useful method to identify the Rhococcus; this gene is unable to differentiate some of Rhodococcus species \[[@bib0075],[@bib0080]\]. Thus, this technique can result in misidentification of species. Up to now, whole genome sequencing (WGS) analysis is consider the trustworthy method to identify the species in this genus \[[@bib0075], [@bib0080], [@bib0085]\]. Moreover, the WGS is not available as routine in most of low income countries. In our case report the 16S rRNA sequencing revealed 100 % of identity with *Rhodococcus hoagii* according to NCBI database.

The development of the infection by *Rhodococcus* occurred later than day 100 in most of cases of HSCT \[[@bib0020],[@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. Regarding risk factors; it has recently been shown, in a case-control study that 02 conditions (diabetes mellitus and a prior opportunistic infection) might increase the risk of infection caused by *Rhodococcus* \[[@bib0015]\]. Other authors, however, did not evidence any risk factors \[[@bib0020],[@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. In our report, the patient was a nurse that lived in urban areas, and stated no recent trips to countryside areas neither contact with animals. Infections caused by Rhodoccous are underreported and probably misdiagnosed because of a conjunction of factors that include the difficult of identification of genus and species by traditional techniques, and the importance of history as previous exposure to rural area, contact with animal as horse which should always prompt investigation. In addition, Rhodococcus is a diverse spectrum of disease \[[@bib0085]\]. Immunocompromised patients can present pneumonia, BSI, malakoplakia and mediastinitis caused by Rhodococcus \[[@bib0085]\]. This clinician characteristic makes the diagnostic hypothesis even more challenging.

Most of the cases reported in transplantation patients described the lung as the mainly route of infection \[[@bib0020],[@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075], [@bib0080], [@bib0085]\]. Around 80 % developed pulmonary cavity, and among immunocompromised populations, it is often observed disseminated disease as well \[[@bib0005]\]. Our patient presented respiratory symptoms but the respiratory cultures were negative. Although, she received a multidrug treatment including antibiotics with action against *Rhococcus* such as linezolid, amikacin and meropenem \[[@bib0065],[@bib0070]\] she evolved to death. The literature recommends at least combination of two antibiotics such as vancomycin, carbapenems, aminoglycosides and quinolones, to treat infections caused by this microorganism \[[@bib0020],[@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. As for systemic infections, monotherapy might result in emergence of resistance \[[@bib0020],[@bib0030],[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070], [@bib0075]\]. But, there is no robust data to stablish the proper antibiotic regime to treat infections caused by this organism.

Conclusion {#sec0020}
==========

Our case-report emphasizes the importance of early diagnosis and the use of 16S rRNA sequencing as a tool to confirmed the identification of species of *Rhodococcus* infection.
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